[go: up one dir, main page]

FI961236A0 - K-252a-derivat som ökar neurotrofininduerad aktivitet - Google Patents

K-252a-derivat som ökar neurotrofininduerad aktivitet

Info

Publication number
FI961236A0
FI961236A0 FI961236A FI961236A FI961236A0 FI 961236 A0 FI961236 A0 FI 961236A0 FI 961236 A FI961236 A FI 961236A FI 961236 A FI961236 A FI 961236A FI 961236 A0 FI961236 A0 FI 961236A0
Authority
FI
Finland
Prior art keywords
derivatives
induced activity
neurotrophin
increase
increase neurotrophin
Prior art date
Application number
FI961236A
Other languages
English (en)
Finnish (fi)
Other versions
FI961236A7 (sv
FI961236L (sv
Inventor
Marcie A Glicksman
David P Rotella
Nicola Neff
Chikara Murakata
Original Assignee
Cephalon Inc
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc, Kyowa Hakko Kogyo Kk filed Critical Cephalon Inc
Publication of FI961236A7 publication Critical patent/FI961236A7/sv
Publication of FI961236A0 publication Critical patent/FI961236A0/sv
Publication of FI961236L publication Critical patent/FI961236L/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI961236A 1993-09-16 1994-09-16 K-252a-derivat som ökar neurotrofininduerad aktivitet FI961236L (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/122,893 US5468872A (en) 1993-09-16 1993-09-16 K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
PCT/US1994/010495 WO1995007911A1 (en) 1993-09-16 1994-09-16 K-252a DERIVATIVES WHICH ENHANCE NEUROTROPHIN-INDUCED ACTIVITY

Publications (3)

Publication Number Publication Date
FI961236A7 FI961236A7 (sv) 1996-03-15
FI961236A0 true FI961236A0 (sv) 1996-03-15
FI961236L FI961236L (sv) 1996-03-15

Family

ID=22405467

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961236A FI961236L (sv) 1993-09-16 1994-09-16 K-252a-derivat som ökar neurotrofininduerad aktivitet

Country Status (14)

Country Link
US (2) US5468872A (sv)
EP (1) EP0719268B1 (sv)
JP (2) JP3943126B2 (sv)
KR (1) KR100186912B1 (sv)
AT (1) ATE203751T1 (sv)
AU (1) AU693480B2 (sv)
CA (1) CA2171561C (sv)
DE (1) DE69427862T2 (sv)
ES (1) ES2160637T3 (sv)
FI (1) FI961236L (sv)
HU (1) HU222570B1 (sv)
NO (1) NO309228B1 (sv)
NZ (2) NZ274355A (sv)
WO (1) WO1995007911A1 (sv)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008809A1 (en) * 1991-11-08 1993-05-13 The University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
EP0675125A1 (en) * 1994-03-18 1995-10-04 Kyowa Hakko Kogyo Co., Ltd. A therapeutic agent for thrombocytopenia and indolocarbazole derivatives
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
AU6733996A (en) * 1995-07-31 1997-02-26 Ciba-Geigy Ag Staurosporine analogues
AU6657596A (en) * 1995-07-31 1997-02-26 Ciba-Geigy Ag Trindene compounds
US5808060A (en) * 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
UA67725C2 (en) * 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
US6875865B1 (en) 1996-06-03 2005-04-05 Cephalon, Inc. Selected derivatives of K-252a
JP4405667B2 (ja) * 1997-12-31 2010-01-27 セフアロン・インコーポレーテツド Ｋ−２５２ａの３’−エピマー誘導体
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
KR100628847B1 (ko) * 1998-09-25 2006-09-29 세파론, 인코포레이티드 감각 유모 세포 및 와우 뉴런의 손상의 예방 또는 치료 방법
WO2000075662A1 (en) * 1999-06-09 2000-12-14 Ljl Biosystems, Inc. Cell-signaling assays
WO2001010440A1 (en) * 1999-08-09 2001-02-15 Trustees Of Dartmouth College COMPOSITIONS AND METHODS TO ENHANCE CANCER CHEMOTHERAPY IN p53 DEFECTIVE TUMORS
FR2798931B1 (fr) 1999-09-22 2001-11-16 Oreal Nouveaux composes indoliques, leur utilisation pour la teinture et le maquillage des matieres keratiniques, compositions les contenant et procedes de teinture
US7129250B2 (en) 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
US6610727B2 (en) 2000-10-06 2003-08-26 Bristol-Myers Squibb Company Anhydro sugar derivatives of indolocarbazoles
US6653290B2 (en) * 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
US6555677B2 (en) * 2000-10-31 2003-04-29 Merck & Co., Inc. Phase transfer catalyzed glycosidation of an indolocarbazole
SK12022003A3 (sk) 2001-03-22 2004-05-04 Bristol-Myers Squibb Company Na topoizomerázu I selektívne cytotoxické cukrové deriváty indolpyrolkarbazolov
US7018999B2 (en) * 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
US20040186044A1 (en) * 2002-11-06 2004-09-23 Cosgaya Jose Miguel Modulation of myelination by interaction with P75 and TRK receptors
WO2004056385A2 (en) 2002-12-20 2004-07-08 Neuronicon Aps Modulation of activity of neurotrophins
ES2537015T3 (es) 2003-03-19 2015-06-01 Biogen Ma Inc. Proteína de unión del receptor de NOGO
EP1776136B1 (en) 2004-06-24 2012-10-03 Biogen Idec MA Inc. Treatment of conditions involving demyelination
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
DK1904104T3 (da) 2005-07-08 2013-11-11 Biogen Idec Inc SP35-antistoffer og anvendelser heraf
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
WO2008013782A2 (en) 2006-07-24 2008-01-31 Biogen Idec Ma Inc. Methods for promoting myelination, neuronal survival and oligodendrocyte differentiation via administration of sp35 or trka antagonists
DK3225251T3 (da) * 2006-12-21 2020-03-16 H Lundbeck As Modulering af pro-neurotrofinaktivitet
WO2009067221A2 (en) * 2007-11-20 2009-05-28 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
ES2326459B1 (es) 2008-04-08 2010-05-28 Universidad De Oviedo Indolocarbazoles glicosilados, su procedimiento de obtencion y sus usos.
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
BRPI0923583A2 (pt) * 2008-12-22 2018-10-09 Creabilis S A síntese de conjugados de polímeros de compostos de indocarbzol.
CN103242404A (zh) * 2012-02-03 2013-08-14 复旦大学 N-鼠李糖基苯并咔唑化合物及其合成方法和在制药中的用途
CA2873623C (en) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
CN103012417B (zh) * 2013-01-08 2015-01-07 中国科学院昆明植物研究所 黄皮属植物中的咔唑生物碱,以其为抗肿瘤活性成分的药物组合物,其制备方法和应用
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60257652A (ja) * 1984-06-02 1985-12-19 Canon Inc 画像処理装置
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
JPH0826036B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US4735939A (en) * 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
DE3835842A1 (de) * 1988-10-21 1990-04-26 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
US5231001A (en) * 1991-03-14 1993-07-27 The United States Of America As Represented By The Department Of Health And Human Services Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
NZ242467A (en) * 1991-07-03 1995-06-27 Regeneron Pharma Methods and compositions using oligonucleotides to treat mammalian tumour cells expressing neurotrophic factors
WO1993008809A1 (en) * 1991-11-08 1993-05-13 The University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
JPH05247056A (ja) * 1992-03-03 1993-09-24 Kyowa Hakko Kogyo Co Ltd インドロカルバゾール誘導体
DE4217963A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Verwendung von Indolocarbazolen zur Behandlung von AIDS
DE4217964A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders

Also Published As

Publication number Publication date
HUT74679A (en) 1997-01-28
EP0719268A1 (en) 1996-07-03
AU7836394A (en) 1995-04-03
WO1995007911A1 (en) 1995-03-23
ES2160637T3 (es) 2001-11-16
CA2171561C (en) 1999-08-03
EP0719268B1 (en) 2001-08-01
KR960704894A (ko) 1996-10-09
DE69427862T2 (de) 2002-04-11
CA2171561A1 (en) 1995-03-23
NZ314037A (en) 2000-09-29
NO309228B1 (no) 2001-01-02
NO961087L (no) 1996-05-13
JP2005220141A (ja) 2005-08-18
FI961236A7 (sv) 1996-03-15
HU222570B1 (hu) 2003-08-28
ATE203751T1 (de) 2001-08-15
KR100186912B1 (ko) 1999-05-01
NZ274355A (en) 1997-03-24
US5468872A (en) 1995-11-21
US5516772A (en) 1996-05-14
DE69427862D1 (de) 2001-09-06
FI961236L (sv) 1996-03-15
AU693480B2 (en) 1998-07-02
JPH09502730A (ja) 1997-03-18
JP3943126B2 (ja) 2007-07-11
HU9600657D0 (en) 1996-05-28
NO961087D0 (no) 1996-03-15

Similar Documents

Publication Publication Date Title
FI961236A0 (sv) K-252a-derivat som ökar neurotrofininduerad aktivitet
DK0640086T3 (da) Mercaptoacetylamido-pyridazo[1,2-a][1,2]diazepin-derivateranvendelige som enkephalinase- og ACE-inhibitorer
DE69825048D1 (de) Analoga von duocarmycin and cc-1065
ITRM940150A0 (it) Procedimento per il trattamento di acque di scarico fortemente colorate.
ITMI930699A1 (it) Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
NO944430L (no) 4-mercaptoacetylamino-[2Åbenzazepinon(3)-derivater, og anvendelse som enkefalinaseinhibitorer
ES2101331T3 (es) Derivados de k-252a.
BR9707659A (pt) Pirrol(2,3-C) carbarzol-6-onas que potencializam atividade atividade de interferon gama
ES2089687T3 (es) 4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa.
DK0706385T3 (da) Anvendelse af isovaleramid som et mildt anxiolytisk og et mildt sedativt middel
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
ES2177783T3 (es) Uso de la gabapentina y sus derivados en el tratamiento de mania y desorden bipolar.
AU2883689A (en) The use of moclobemide to treat or prevent cognitive disorders
NO953989D0 (no) Nye polysykliske systemer og derivater derav, som neurotransmitter frigivelses-forsökende midler som er anvendbare ved behandling av kognitive sykdommer
DK0391185T3 (da) 1,8-Naphthyridiner
ID23175A (id) Penggunaan benzopiranol untuk mengobati gangguan syaraf
NO953892D0 (no) Imidazolokinoksalinon-derivater som EAA-antagonister
PT935598E (pt) Derivados de 3-oxo-pirido (1,2-a)benzimidazole-4-carboxamida alquilo substituidos contendo 5 heteroatomos uteis no tratamento de disturbios do sistema nervoso central
AU7025087A (en) Pharmaceutical compositions for the therapy of cerebropathies on functional and organic base
DE69516467D1 (de) Feste Lösungen von Pyrrolo-(3,4-c)-pyrrolen mit Chinacridonchinonen
MX9307679A (es) Derivados de furanona utiles en terapia.
ZA893606B (en) Use of diazepinones for treating disorders of the microcirculation
DK0574857T3 (da) Polycycliske 31668P- og 31668U-forbindelser, fremgangsmåder til deres fremstilling samt deres anvendelse som antibiotiske eller antitumorale lægemidler
FR2700544B1 (fr) Dérivés de 9H-imidazo[1,2-a]benzimidazole-3-acétamide, leur préparation et leur application en thérapeutique.
FR2707987B1 (fr) Dérivés de 9H-imidazo[1,2-a]benzimidazole-3-acétamide, leur préparation et leur application en thérapeutique .